{"id":475813,"date":"2020-03-24T14:02:01","date_gmt":"2020-03-24T14:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475813"},"modified":"2020-03-24T14:02:01","modified_gmt":"2020-03-24T14:02:01","slug":"thymidine-kinase-2-deficiency-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/thymidine-kinase-2-deficiency-market-insights-epidemiology-and-market-forecast2030_475813.html","title":{"rendered":"Thymidine Kinase 2 Deficiency Market Insights, Epidemiology, and Market Forecast-2030"},"content":{"rendered":"
\"Thymidine<\/a><\/div>\n

(Albany, US) DelveInsight has launched a new report on Thymidine Kinase 2 Deficiency Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Thymidine Kinase 2 Deficiency Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Thymidine Kinase 2 Deficiency , historical and forecasted epidemiology as well as the Thymidine Kinase 2 Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Thymidine Kinase 2 Deficiency market report provides current treatment practices, emerging drugs, Thymidine Kinase 2 Deficiency (TK2D) market share of the individual therapies, current and forecasted Thymidine Kinase 2 Deficiency (TK2D) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Thymidine Kinase 2 Deficiency (TK2D) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Thymidine kinase 2 deficiency (TK2d) is a sporadic genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. It was first diagnosed in children in 2001 whereas improved genetic testing led to the discovery of an
adult form of TK2d in 2013. Common symptoms of TK2d are muscle weakness that gets worse over time, low muscle tone (hypotonia, also called floppy baby syndrome), trouble breathing, problems chewing and swallowing, loss of motor skills (like crawling, walking, balancing, and grabbing), poor reflexes, neurological effects, such as seizures or altered brain activity and function, slowed mental development, hearing loss, ptosis, inability to move the eyes and eyebrows, etc.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- Thymidine Kinase 2 Deficiency free sample page<\/a><\/strong><\/p>\n

 <\/p>\n

Thymidine Kinase 2 Deficiency Epidemiology<\/strong><\/p>\n

The Thymidine Kinase 2 Deficiency (TK2D) epidemiology division provide insights about historical and current Thymidine Kinase 2 Deficiency (TK2D) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  <\/p>\n

 <\/p>\n

Report Key facts:- <\/strong><\/p>\n

1. As per study by Domínguez-González,C.et al. (2019), The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.<\/p>\n

2. As per the study titled “TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form”, conducted by Wang et al. (2018), the disorder appears to be rare, with approximately 107 affected individuals with a molecularly confirmed diagnosis.<\/p>\n

 <\/p>\n

“As per the study titled “Retrospective natural history of thymidine kinase 2 deficiency”, conducted by Garone et al. (2017), 92 patients with genetically confirmed diagnoses of TK2 deficiency were identified in which 67 were from the literature review and 25 were from unreported cases”<\/strong><\/em><\/p>\n

 <\/p>\n

Table of Content<\/strong><\/em><\/a><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of Thymidine Kinase 2 Deficiency (TK2D)<\/p>\n

3. Competitive Intelligence Analysis for Thymidine Kinase 2 Deficiency (TK2D)<\/p>\n

4. Thymidine Kinase 2 Deficiency (TK2D) : Market Overview at a Glance<\/p>\n

4.1. Thymidine Kinase 2 Deficiency (TK2D) Total Market Share (%) Distribution in 2017<\/p>\n

4.2. Thymidine Kinase 2 Deficiency (TK2D) Total Market Share (%) Distribution in 2030<\/p>\n

5. Thymidine Kinase 2 Deficiency (TK2D) : Disease Background and Overview <\/p>\n

6. Patient Journey<\/p>\n

7. Thymidine Kinase 2 Deficiency (TK2D) Epidemiology and Patient Population<\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Thymidine Kinase 2 Deficiency (TK2D) Treatment and Management<\/p>\n

8.2. Thymidine Kinase 2 Deficiency (TK2D) Treatment Algorithm <\/p>\n

9. Unmet Needs<\/p>\n

10. Key Endpoints of Thymidine Kinase 2 Deficiency (TK2D) Treatment<\/p>\n

11. Marketed Products<\/p>\n

12. Emerging Therapies<\/p>\n

13. Thymidine Kinase 2 Deficiency (TK2D) : Seven Major Market Analysis<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/p>\n

15.1. United States: Market Size<\/p>\n

16. Access and Reimbursement Overview of Thymidine Kinase 2 Deficiency (TK2D)<\/p>\n

17. KOL Views<\/p>\n

18. Market Drivers<\/p>\n

19. Market Barriers<\/p>\n

20. Appendix<\/p>\n

20.1. Bibliography<\/p>\n

20.2. Report Methodology<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/a><\/strong><\/p>\n

 <\/p>\n

Why should you buy this report here ?<\/strong><\/p>\n